Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis
Open Access
- 1 October 2003
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 32 (8) , 795-800
- https://doi.org/10.1038/sj.bmt.1704230
Abstract
Cytomegalovirus viral load measurement is a powerful new tool for monitoring of CMV disease; however, the optimal strategy for use is unknown. Weekly plasma CMV viral loads and CMV-related outcomes were monitored in 46 consecutive allogeneic bone marrow transplantation (BMT) recipients receiving standardised antiviral prophylaxis. A total of 412 CMV viral loads were quantitated in the first 100 days post transplantation with 77 positive samples (19%) in 20 patients (43%). No patient with all negative CMV viral load results developed CMV disease. Two of three patients with highly positive CMV viral loads (first positive ⩽30 days post transplant, maximum viral load ⩾5000 copies/ml, and ⩾50% of samples positive) developed CMV disease. A total of 17 patients with positive CMV viral loads, who did not meet the criteria for highly positive, did not develop CMV disease. CMV viral load detection was higher in recipients who were CMV sero-positive. In conclusion, CMV disease did not occur in the setting of a persistently negative CMV viral load. A positive CMV viral load result occurred commonly after allogeneic BMT, even in patients receiving antiviral prophylaxis.Keywords
This publication has 12 references indexed in Scilit:
- INCREASED HUMAN CYTOMEGALOVIRUS (HCMV) DNA LOAD IN PERIPHERAL BLOOD LEUKOCYTES AFTER LUNG TRANSPLANTATION CORRELATES WITH HCMV PNEUMONITIS1Transplantation, 2001
- Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infectionBone Marrow Transplantation, 2001
- Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantationThe Lancet, 2000
- Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapyTransplant Infectious Disease, 1999
- The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantationBone Marrow Transplantation, 1998
- RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1Transplantation, 1998
- Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV diseaseBone Marrow Transplantation, 1998
- CYTOMEGALOVIRUS PNEUMONIA AFTER BONE MARROW TRANSPLANTATIONTransplantation, 1993
- IMMUNE DONORS CAN PROTECT MARROW-TRANSPLANT RECIPIENTS FROM SEVERE CYTOMEGALOVIRUS INFECTIONSThe Lancet, 1987
- Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host diseaseBlood, 1986